Trulieve Q2: 60% Margins Look Great, but Restructuring Fog Is Clouding the Stock

Trulieve's medical business posted solid numbers, but the market stayed cautious

Trulieve's second quarter showed a healthier medical operation, yet the stock still traded around the noise from restructuring. For investors, the key question is no longer just how the quarter looked on paper. It is whether the cleaned-up business is now easy to underwrite.

Strong earnings power did not stop a sell-off

Trulieve posted adjusted EPS of $0.11, which beat analyst estimates by 37.5%. The quarter also included 60% gross margin, cash flow from operations of $53 million, and free cash flow of $32 million. Even so, the market reaction was negative, with shares down 2.94% to $8.7352 after the announcement. The operating numbers held up, but investors still appear hesitant around the new corporate structure.

Harvest deconsolidation left a cleaner story, and a messier read-through

The market's hesitation is less about the medical franchise itself and more about whether the restructured company is now simpler to value. Trulieve completed the deconsolidation of Harvest on June 3, 2026, and the quarter still reported a net loss attributable to common shareholders of $406 million or $2.10 per share, includes $407 million impact from the Harvest deconsolidation and equity investment.

That creates two reasonable readings. Supporters can argue the medical business is finally separated and easier to track. Skeptics can argue the new structure still needs time to prove itself. The stock trading approximately 34% below its 52-week high of $13.28 suggests investors are still waiting for clarity.